Dunia Hernandez, MD
Nephrology · Pembroke Pines, FLNPI 1750672135
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 35.9% of the total. 2025 is the largest year on record at $704, 9.6 times the $74 reported in 2019.
Across 134 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$1K
- Bayer$289
- Amgen$210
- Boehringer Ingelheim$178
- Aurinia Pharma U.S., Inc.$157
- Insmed, Inc.$119
- plus $934 from 23 others
Across 56 payments — averaging $4253.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$238K
- Amgen$290
- Eli Lilly$187
What the payments were for
- Food & beverage$2,91099%
- Education$331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 44 | $1,057 |
| Bayer | 15 | $289 |
| Amgen(2 entities) | 10 | $210 |
| Boehringer Ingelheim | 9 | $178 |
| Aurinia Pharma U.S., Inc. | 7 | $157 |
| Insmed, Inc. | 1 | $119 |
| Novo Nordisk | 6 | $111 |
| Otsuka America Pharmaceutical, Inc. | 5 | $98 |
| Calliditas Therapeutics US Inc. | 4 | $92 |
| AstraZeneca | 4 | $75 |
| Ardelyx, Inc. | 3 | $66 |
| Boston Scientific | 3 | $64 |
| Pfizer | 3 | $57 |
| Amarin Pharma, Inc. | 3 | $52 |
| Abbott | 1 | $45 |
| Novartis | 2 | $30 |
| Genentech USA, Inc. | 1 | $24 |
| Angiodynamics, Inc. | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $24 |
| Mylan Specialty L.p. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| AbbVie | 1 | $17 |
| GSK | 1 | $16 |
| Cvrx, Inc. | 2 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
How this compares
$2,943 in reported general payments places this provider in the 65th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 40 | $35,423 |
| JardianceEmpagliflozin | 26 | $30,147 |
| JanuviaSitagliptin Phosphate | 16 | $24,190 |
| EliquisApixaban | 20 | $23,481 |
| KerendiaFinerenone | 13 | $18,444 |
| EntrestoSacubitril/Valsartan | 16 | $11,839 |
| XareltoRivaroxaban | 11 | $9,184 |
| SynthroidLevothyroxine Sodium | 13 | $1,481 |
| Atorvastatin Calcium | 130 | $1,310 |
| Nifedipine ErNifedipine | 55 | $1,167 |
| Torsemide | 43 | $794 |
| Rosuvastatin Calcium | 43 | $743 |
| Metoprolol Succinate | 55 | $572 |
| Levothyroxine Sodium | 41 | $487 |
| Amlodipine Besylate | 100 | $465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $75 | $35,42340 claims |
| Boehringer IngelheimJardiance | $178 | $30,14726 claims |
| PfizerEliquis | $57 | $23,48120 claims |
| BayerKerendia | $289 | $18,44413 claims |
| NovartisEntresto | $30 | $11,83916 claims |
| Johnson & JohnsonXarelto | $12 | $9,18411 claims |
| AbbVieSynthroid | $17 | $1,48113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 756 nephrology providers in Florida.
Other nephrology in Pembroke Pines
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
- Fouad ChebibJacksonville$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.